2026-10-10T21:42:38Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33966645 2026-09-22T17:22:29Z category_7 category_19 category_734 category_64 category_106 portal_5 item_type_3 month_year_09_2026

<p>Estimated cost per patient per administration modality, type of cost and cycle.</p> María Lloret Avellá (25091061) Mafalda Carmo (13759307) Núria Paladio Duran (25091064) Pere Blancher Parcerisa (25091067) Medicine Pharmacology Biological Sciences not elsewhere classified Cancer Science Policy therapeutically equivalent alternative standard therapeutic options infection risk declined improve patient convenience healthcare professional time frees hospital capacity constrained health system acute myeloid leukemia 61 %), transport 50 fewer hours treatment &# 8209 non &# 8209 micro &# 8209 integrating oral hmas 8 &# 8211 58 &# 8211 4 &# 8211 13 &# 8211 11 &# 8211 aml care within resource &# 8209 spain </ p representing cost reductions 9 %&# 8211 22 %), infections standard intensive chemotherapy catheter use decreased drug acquisition costs aml patients unfit oral versus intravenous oral hma administration resource use &# 8364 intensive chemotherapy oral decitabine drug preparation drug costs subsequent cycles study estimated related hospitalizations related costs related activities organizational impact medical transportation hypomethylating agents <p>Estimated cost per patient per administration modality, type of cost and cycle.</p> 2026-09-22T17:22:18Z Dataset Dataset 10.1371/journal.pone.0358426.t003 https://figshare.com/articles/dataset/_p_Estimated_cost_per_patient_per_administration_modality_type_of_cost_and_cycle_p_/33966645 CC BY 4.0